Health and Fitness Health and Fitness
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012
Tue, October 23, 2012

Sarepta Therapeutics to Present Company Overview at the 2012 Lazard Capital Markets 9th Annual Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. al-markets-9th-annual-healthcare-conference.html
Published in Health and Fitness on Tuesday, November 6th 2012 at 5:48 GMT by Market Wire   Print publication without navigation


November 06, 2012 08:30 ET

Sarepta Therapeutics to Present Company Overview at the 2012 Lazard Capital Markets 9th Annual Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Nov 6, 2012) -  Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 Lazard Capital Markets 9th Annual Healthcare Conference in New York, NY on Tuesday, November 13, 2012 at 4:30 p.m. Eastern Time. Chris Garabedian, Sarepta's president and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources